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Immunity in the urinary tract has distinct and poorly
understood pathophysiological characteristics and
urinary tract infections (UTIs) are important causes
of morbidity and mortality. We investigated the role
of the soluble pattern recognition molecule pentraxin
3 (PTX3), a key component of the humoral arm of
innate immunity, in UTIs. PTX3-deficient mice
showed defective control of UTIs and exacerbated
inflammation. Expression of PTX3 was induced in
uroepithelial cells by uropathogenic Escherichia coli
(UPEC) in a Toll-like receptor 4 (TLR4)- and MyD88-
dependent manner. PTX3 enhanced UPEC phagocy-
tosis and phagosome maturation by neutrophils.
PTX3 was detected in urine of UTI patients and
amounts correlated with disease severity. In cohorts
of UTI-prone patients, PTX3 gene polymorphisms
correlated with susceptibility to acute pyelonephritis
and cystitis. These results suggest that PTX3 is an
essential component of innate resistance against
UTIs. Thus, the cellular and humoral arms of innate
immunity exert complementary functions in medi-
ating resistance against UTIs.
INTRODUCTION
The urinary tract is normally sterile and has unique anatomical
and functional properties that call for specialized defense mech-
anisms and immunoregulation (Chan et al., 2013; Dhakal et al.,
2008; Ragnarsdo´ttir et al., 2011). Despite improved hygiene
and widespread use of antibiotics, urinary tract infections(UTIs) remain a major public health problem, causing consider-
able morbidity and mortality (Foxman, 2002). UTIs are mainly
caused by uropathogenic strains of Escherichia coli (UPEC)
and can progress to acute pyelonephritis (APN) that gives rise
to severe morbidity such as renal failure, bacteremia, and shock
(Foxman, 2002; Ragnarsdo´ttir et al., 2011; Sivick and Mobley,
2010). UTIs can induce a robust innate immune response char-
acterized by Toll-like receptor (TLR) activation and production
of antimicrobial peptides (e.g., cathelicidin), cytokines (e.g.,
G-CSF or IL-17), and chemokines (e.g., CCL2, CXCL1, CXCL2)
(Chromek et al., 2006; Fischer et al., 2006; Frende´us et al.,
2000; Hang et al., 1999; Ingersoll et al., 2008). UPEC have devel-
oped strategies to bypass and tame the host innate immune
response, including inhibition of NF-kB (Billips et al., 2007) and
of TLR signaling (Cirl et al., 2008; Yadav et al., 2010). Cellular
innate immunity and cell-associated receptors play an important
role in defense against UTIs. In particular, TLR4-, TLR5-, and
TLR11-deficient or defective mice show impaired UTI clearance
and defective proinflammatory response and leukocyte recruit-
ment (Andersen-Nissen et al., 2007; Schilling et al., 2001; Zhang
et al., 2004). In contrast, the role, if any, of the humoral arm of
innate immunity (Bottazzi et al., 2010) at this anatomical site
remains to be defined.
Soluble pattern recognition molecules (PRMs), including
collectins, ficolins, and pentraxins (PTXs), act as functional
ancestors of antibodies and constitute with the complement
cascade, the humoral arm of the innate immune system (Bottazzi
et al., 2010). Pentraxins are a superfamily of multifunctional mul-
timeric proteins, which are phylogenetically conserved from
arachnids to mammals and are divided into short (C-reactive
protein [CRP] and serum amyloid P component [SAP]) and
long pentraxins (Bottazzi et al., 2010). The prototypic long pen-
traxin, PTX3, is a multifunctional multimeric protein highly
conserved between mouse and man. PTX3 is produced by
diverse cell types (e.g., monocytes, macrophages, endothelialImmunity 40, 621–632, April 17, 2014 ª2014 Elsevier Inc. 621
Figure 1. Susceptibility of Ptx3–/– Mice
to UTIs
(A and B) CFU in bladders (A) and kidneys (B)
harvested from Ptx3+/+ and Ptx3–/– mice infected
transurethrally with 1 3 108 E. coli (CFT073).
Tissues were collected at day 1 and day 5 after
infection. Data shown are values of individual mice
and are an uncensored pool of three experiments
performed with similar results. Kidney CFUs were
measured only in an unselected fraction of the
mice. Themedian value is shown. *p% 0.05; **p%
0.01; two-tailed Mann-Whitney U test.
(C) Analysis of body weight variation in Ptx3+/+ and
Ptx3–/– mice (n = 14) after transurethral infection.
Results are mean ± SEM. *p % 0.05; two-tailed
Student’s t test.
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PTX3 in Urinary Tract Infectioncells) on demand (i.e., in a gene-expression-dependent manner
in response to extracellular signals) and it is stored in mature
neutrophils for a rapid release (Bottazzi et al., 2010). PTX3 inter-
acts with selected pathogens (e.g., Aspergillus fumigatus, Pseu-
domonas aeruginosa), has opsonic activity, and promotes their
phagocytosis and clearance (Garlanda et al., 2002; Jaillon
et al., 2007; Moalli et al., 2010, 2011). Gene-modified mice
have demonstrated that PTX3 plays a nonredundant protective
role against bacterial and fungal infections and participates in
tuning of the inflammatory response (Deban et al., 2010;
Garlanda et al., 2002; Souza et al., 2009).
By using a murine model of urinary tract infection, we
observed a rapid local and systemic increase of PTX3 concen-
trations that correlated with severity of the infection. PTX3-
deficient mice presented impaired clearance of UTIs and an
increased UPEC-induced inflammatory response. PTX3 bound
UPEC, increased their phagocytosis by human and murine
neutrophils, and accelerated phagosomematuration. Unexpect-
edly, both hematopoietic and nonhematopoietic cell-derived
PTX3 was required for protection against UTIs. PTX3 was
produced by the urothelium downstream of the protective
TLR4-MyD88 pathway. Finally, we report that PTX3 concentra-
tions increased in the serum and urine of patients with UTIs
and correlated with the severity of the infection and that PTX3
gene polymorphisms were associated with susceptibility to
UTIs. Thus, PTX3 is a humoral pattern recognition molecule
shown to be involved in innate immunity against UTIs. The
cellular and humoral arms of innate immunity exert complemen-
tary functions in mediating resistance against UTIs.
RESULTS
Susceptibility of Ptx3–/– Mice to UTIs
In order to define the involvement of PTX3 in UTIs, we first
analyzed systemic and local PTX3 expression in a mouse model
of transurethral infection and ascendant pyelonephritis. An early
and marked increase of blood and tissue (bladder and kidney)
concentrations of PTX3 was observed in UPEC-infected mice
(Figures S1A–S1C available online). Systemic and local
PTX3 concentrations returned to basal values at day five postin-
fection (D5).
We then analyzed the UTI susceptibility of Ptx3/ mice. As
previously reported (Bottazzi et al., 2010), Ptx3 deficiency in622 Immunity 40, 621–632, April 17, 2014 ª2014 Elsevier Inc.two genetic backgrounds was not associated with spontaneous
urinary tract infection and inflammation. In the UTI challenge
model, given the intragroup variability resulting from the experi-
mental procedure (transurethral catheterization and challenge)
(Andersen-Nissen et al., 2007; Chromek et al., 2006), we con-
ducted three independent experiments with similar results.
Results presented in Figure 1 are uncensored pooled values of
individual mice. On day 1 after infection (D1), no significant differ-
ence in terms of bacterial burden was observed in the bladders
of wild-type and Ptx3/ mice (Figure 1A). In contrast, on day 5
postinfection, wild-type mice had a median of 8.66 3 103 CFU/
bladder (interquartile range [IQR] 5.533 105  1,140) compared
to 1.343 106 CFU/bladder (IQR 1.733 107  10,615) in Ptx3/
mice (p = 0.02; Figure 1A). We next analyzed the susceptibility of
Ptx3/ mice to pyelonephritis. Kidney bacterial burden was
already significantly higher in Ptx3/ mice on D1 (median
1.393 105; IQR 2.23 106 10, p = 0.03) and then on D5 (median
1.18 3 106; IQR 2.1 3 107  4.3 3 103, p = 0.005) compared to
wild-type mice (median 1; IQR 1.383 105  1 at D1 and median
620; IQR 1.04 3 105  1 at D5) (Figure 1B). The lack of a statis-
tically significant difference in bladder bacterial numbers on D1
between Ptx3+/+ and Ptx3/ mice, with a concomitant signifi-
cant difference in the kidneys, may in part be related to similar
levels of initial binding to urothelium. Moreover, macroscopic
kidney abscessesweremore frequent inPtx3/mice compared
to wild-type animals (D5, Table S1). The increase in UTI suscep-
tibility of Ptx3/ mice was also manifested as increased body
weight loss starting already on day 1 after infection and as failure
to recover at later times (Figure 1C). Thus, PTX3 is locally and
systemically expressed during UTIs and plays a pivotal role in
defense against UPEC.
Opsonic Activity of PTX3 for UPEC
In an effort to define the mechanisms responsible for the protec-
tive action of PTX3 against UTIs, binding to UPEC and opsonic
activity were studied as previously described (Moalli et al.,
2010, 2011). Recombinant PTX3 bound to the UPEC strain in a
dose-dependent manner (Figure 2A). PTX3 eluted from bacteria
wasmainly in themonomeric form of47 kDa but also in dimeric
and trimeric form (86 kDa and 128 kDa). Endogenous PTX3,
present in normal human serum at low concentrations (<2 ng/ml),
bound to UPEC and was detectable in the eluted fraction
(Figure 2A).
Figure 2. Binding of PTX3 to E. coli CFT073 Increased Phagocytosis and Accelerated Phagosome Maturation by Human and Mouse
Neutrophils
(A) Immunoblotting analysis of PTX3 eluted from CFT073 incubated for 1 hr with recombinant PTX3 at the indicated concentration or normal human serum (10%).
(B–D) In vitro phagocytosis of CFSE-labeled E. coli strain CFT073, opsonized or not (none) with PTX3, by mouse (Ptx3+/+ or Ptx3/) (B, C) and human (D)
neutrophils was analyzed by FACS. Similar results were obtained with bacteria labeled with the pH-insensitive dye Alexa Fluor 647 and phagocytosed by human
neutrophils (data not shown).
(E) Phagosome maturation was analyzed by fluorescence confocal microscopy. Human neutrophils were incubated with Alexa Fluor 647-labeled CFT073
(opsonized or not [none] with PTX3 [0.21 3 106 mol/l]) and phagocytosis synchronized by centrifugation. After 5 or 45 min, cells were stained with antibodies
EEA1, MPO, and LAMP1. Each dot represents the MFI of the three protein markers found in single bacteria-containing endosomes evaluated separately.
(F) Representative images of phagosomes analyzed in (E).
(B–E) Data are expressed as the percentage of mean of control MFI. The mean value ± SEM is shown; *p% 0.05; **p% 0.01; ***p% 0.001; two-tailed Student’s
t test.
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PTX3 in Urinary Tract InfectionWhen mouse cells were considered (Figures 2B and 2C),
Ptx3/ neutrophils had defective phagocytic activity after
15min of coincubation, suggesting a primary role of endogenous
PTX3 stored in neutrophils (Jaillon et al., 2007). At 30 min, Ptx3-
competent and -incompetent neutrophils showed similar levels
of phagocytosis, suggesting that, in a test tube, under these
in vitro conditions, the same plateau of ingestion is eventually
reached (Figures 2B and 2C). Opsonization of UPEC by PTX3
dramatically increased phagocytosis by Ptx3+/+ and Ptx3/
neutrophils (Figures 2B and 2C). PTX3 opsonization amplified
UPEC phagocytosis by human neutrophils in a dose-dependent
manner (Figure 2D). The lowest effective dose (1.703 109mol/l,
80 ng/ml) was in the range of that found in kidney, bladder, urine,
and blood during UTIs (Figures S1A–S1C and data not shown).
We then investigated whether PTX3 opsonization affected the
intracellular handling of bacteria in neutrophils. Phagosome
maturation was monitored with EEA1 and LAMP1 (early endoso-
mal and lysosomal markers, respectively) and with myeloperox-
idase (MPO), stored in granules that rapidly fuse with the
phagosome (Nordenfelt and Tapper, 2011). PTX3 opsonization
accelerated phagosome maturation as suggested by earlier
EEA1 loss and MPO acquisition in phagosomes at 5 min and
higher LAMP1 expression at 45 min (Figures 2E and 2F). There-
fore, endogenous PTX3 arms neutrophils for early accelerated
disposal of UPEC and exogenous PTX3 results in higher and sus-
tained phagocytic activity and earlier phagosome maturation.
Cellular Source and Pathway for PTX3 Production
in UTIs
To dissect the origin of PTX3 in UTIs, serum and urine amounts
were measured in mice infected transurethrally or injected i.p.
with LPS (2 mg/mouse, i.p.). PTX3 amounts in serum and tissues
were measured by ELISA (D’Angelo et al., 2009; Souza et al.,
2009). We found that normal mouse urine markedly quenched
detection by ELISA of recombinant PTX3 used as standard refer-
ence. Therefore, the presence of PTX3 in mouse urine was
assessed by immunoblotting. After systemic LPS administration
or UTI, PTX3 amounts in serum increased rapidly (Figure 3A). In
contrast, PTX3 in urine increased only after UTI and not after
systemic LPS administration (Figure 3B). Titration using various
concentrations of recombinant PTX3 in normal urine led to an
estimate of 50–80 ng/ml PTX3 in mouse urine during UTIs (data
not shown).
Infiltrating leukocytes as well as epithelial cells could
contribute to PTX3 levels in the urinary tract. Immunohistochem-
ical analysis showed little or no PTX3 in normal bladder or kidney
(Figure 3C). On day 0.25 after UTI, immune reactivity was asso-
ciated with epithelial cells in the kidney. A strong interstitial
staining was observed in the bladder, associated with infiltrating
inflammatory cells (Figure 3C). On day 1, PTX3 staining was
mainly associated with kidney and bladder epithelial cells and
with infiltrating inflammatory cells (Figure 3C). In contrast,
glomerular cells were essentially negative or presented a very
faint positivity, consistent with the localization of ascending
infection to the urinary tract mucosa and kidney tubuli. The
dose of LPS used was sufficient to increase the levels of PTX3
in blood but not in urine (Figures 3A and 3B), and, unlike UPEC
strain, LPS did not induce PTX3 expression in bladder and
kidney nor neutrophil migration in urine (Figures 3C and 3D).624 Immunity 40, 621–632, April 17, 2014 ª2014 Elsevier Inc.To further assess the capacity of urothelial cells to produce
PTX3, a nonmalignant human urothelial cell line, HCV29, was
used. HCV29 cells produced PTX3 constitutively and this was
further increased by IL-1b or TNF-a (Figure 4A), two cytokines
present in the urinary tract during UTIs (Ingersoll et al., 2008),
and by UPEC (Figure 4B). Pretreatment of urothelial cells with
the transcriptional inhibitor actinomycin D totally blocked the
TNF-a-induced PTX3 secretion, suggesting a role for de novo
gene expression (Figure S3). These results suggest that uroepi-
thelial cells and infiltrating leukocytes are the main source of
PTX3 in the urinary tract during UTIs.
In an effort to assess the receptor(s) and signaling pathways
responsible for PTX3 induction in uroepithelial cells, the HCV29
nonmalignant cell line was used. HCV29 uroepithelial cells ex-
press MyD88, TRIF, and all TLRs at variable levels, with the
exception of TLR8 (Figure S4). In order to evaluate the signaling
pathway(s) leading to PTX3 expression, we silenced MyD88,
TRIF, and TLRs in HCV29 urothelial cells and analyzed PTX3 pro-
duction induced by UPEC. Only silencing of TLR4 and MyD88
abrogated PTX3 induction (Figure 4C). Furthermore, IL-1Ra
and anti-TNF-a blocking mAb did not reduce PTX3 production,
excluding indirect induction mediated by IL-1b or TNF-a
expressed by HCV29 urothelial cells (Figures 4C and S4).
Consistent with these in vitro data, PTX3 production was abro-
gated in Myd88/ mice both in kidneys and bladder but not in
Irf3/ and Il1r1/ mice (Figure 4D). Together, these data
suggest that PTX3 response in UTIs is regulated by the TLR4-
MyD88 axis. In contrast, the IL-1R1-MyD88 pathway, which
regulates PTX3 in other pathological conditions (Salio et al.,
2008), the TLR-IRF pathway, and TNF-a were irrelevant for
PTX3 induction in UTIs (Figures 4C and 4D).
Role of Hematopoietic versus Nonhematopoietic
Cell-Derived PTX3
We next investigated the contribution of PTX3 derived from
hematopoietic or nonhematopoietic cells in the defense against
UTIs by using bone marrow chimeras. Wild-type mice that had
received either Ptx3/ or wild-type bone marrow cells had a
lower bacterial load than did Ptx3/ mice reconstituted with
either Ptx3/ or wild-type bone marrow cells (Figure 4E),
suggesting a major role for epithelial cell-derived PTX3. How-
ever, mixed chimeras were protected against kidney abscess
formation compared to Ptx3/ mice receiving Ptx3/ bone
marrow cells (Table S2). Thus, PTX3 derived from both hemato-
poietic and epithelial cells played a role in controlling abscess
formation.
Inflammation in PTX3-Deficient Mice
Striking a balance between amplification of protective innate
immunity and uncontrolled inflammation is key to resistance
against UTIs (Ragnarsdo´ttir et al., 2011). Therefore, we next
analyzed whether the inflammatory response to a UTI was differ-
entially modulated in Ptx3/ mice. Histological analysis of
bladder sections revealed submucosal edema and infiltration of
the submucosa and epithelium by leukocytes on days 0.25 and
1 postinfection (Figure 5A). On D5, high levels of leukocyte infil-
tration were still found in bladder and kidney sections of Ptx3/
mice, whereas inflammation was minimal in wild-type mice (Fig-
ure 5A). Higher levels of CCL2, CXCL2, and CXCL1 in tissues
Figure 3. Cellular Source of PTX3 in UTIs
(A) Wild-type mice were transurethrally infected with 1 3 108 E. coli (CFT073) or received one administration of LPS (2 mg/mouse i.p). Sera were harvested at
indicated time and PTX3 levels analyzed by ELISA.
(B) Urine was harvested 8 hr after injection or infection and PTX3 analyzed by immunoblotting (15 mg of protein/lane, top). Optical density of the immunoreactive
bands was quantified by an image analysis software (ImageJ, NIH, Bethesda, MD) (bottom). Ponceau Red staining shows major urinary proteins (also known as
a2u-globulins; 20 kDa).
Results are mean ± SEM (n = 4); *p% 0.05; **p% 0.01; ***p% 0.001; two-tailed Student’s t test.
(C) Immunostaining analysis for Ptx3 in kidney and bladder sections of wild-type noninfected mice, mice transurethrally infected with 13 108 E. coli (CFT073), or
mice injected with LPS (2 mg/mouse i.p). Scale bars represent 100 mm.
(D) Neutrophil counts in urine of wild-type mice transurethrally infected with 13 108 E. coli (CFT073) or injected with LPS (2 mg/mouse by i.p.). The mean value ±
SEM is shown. ***p% 0.001; two-tailed Mann-Whitney U test.
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PTX3 in Urinary Tract Infection(Figure 5B) and higher neutrophil recruitment in urine were
observed in Ptx3/ mice compared to control mice (Figures
5C and 5D). Urine and tissue neutrophils increased rapidly and
transiently in wild-type mice, whereas they remained high until
day 5 postinfection in Ptx3/ mice (Figures 5C and 5D). Similar
results were obtained by measuring the levels of Ly6G-positive
area in tissues (data not shown). When mice were infected with
the prototypic asymptomatic bacteriuria (ABU) strain E. coli83972, which lacks functional UTI-associated virulence factors
(Klemm et al., 2006; Wullt et al., 2000), the infection levels and
the inflammatory response (i.e., chemokine levels in bladders
and neutrophil counts in urine) were low and comparable in the
two genotypes (Figure S6). These results suggest that the exac-
erbated inflammation in PTX3-deficient mice during UTIs is
secondary to defective recognition and clearance of the patho-
genic strain.Immunity 40, 621–632, April 17, 2014 ª2014 Elsevier Inc. 625
Figure 4. PTX3 Production by Urothelial Cells and Role of Hematopoietic versus Nonhematopoietic Cell-Derived PTX3 in UTIs
(A) PTX3 mRNA and protein produced by HCV29 cells stimulated or not with IL-1b or TNF-a at the indicated time and concentration.
(B) PTX3 mRNA and protein produced by HCV29 cells stimulated for 2 hr with E. coli strain CFT073 (MOI 0.5).
Results are mean ± SEM (n = 4); *p% 0.05; **p% 0.01; ***p% 0.001; one-tailed Student’s t test.
(C and D) Pathway of PTX3 induction in UTIs.
(C) TRIF, MyD88, and TLR1-10 were silenced by siRNAs in HCV29 cells. Cells were also treated with anti-TNF-a blocking mAb (Infliximab) or IL-1Ra (Anakinra) to
block TNF-a and IL-1b, respectively. PTX3 production was analyzed by ELISA in supernatant of cells stimulated or not for 2 hr with E. coli strain CFT073 (MOI 0.5).
Results are expressed as percentage of control scramble siRNA or isotype antibody (two experiments in triplicate).
(D) PTX3 levels in bladder and kidney homogenates of wild-type,Myd88/, Irf3/, and Il1r1/mice (n = 5–19) are expressed as the percentage of the mean of
noninfected control mice.
Results are mean ± SEM. *p% 0.05; **p% 0.01; ***p% 0.001; two-tailed Student’s t test.
(E) Kidney CFU in lethally irradiated Ptx3+/+ and Ptx3–/– that received Ptx3+/+ or Ptx3–/– bone marrow cells. Tissues were harvested at day 5 after transurethral
infection. The median value is shown. *p% 0.05; **p% 0.01; two-tailed Mann-Whitney U test.
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Figure 5. Inflammatory Response during
UTIs in Ptx3+/+ and Ptx3–/– Mice
(A) Histological analysis of H&E-stained bladder
and kidney sections fromPtx3+/+ andPtx3/mice
transurethrally infected with 1 3 108 E. coli
(CFT073). Bladders (top) were harvested at day
0.25, day 1, or day 5 after infection. *Bladder
submucosa with inflammatory infiltrate; **transi-
tional bladder epithelium with inflammatory
infiltrate. Kidneys (bottom) were harvested at day 5
after infection. *Renal medulla with inflammatory
infiltrate; **renal pelvis with inflammatory infiltrate
(OM103). Scale bars represent 100 mm.
(B) Chemokine levels in homogenized Ptx3+/+ and
Ptx3/ bladders and kidneys 24 hr after infection.
Results are mean ± SEM. *p % 0.05; two-tailed
Student’s t test.
(C) Neutrophil counts in urine of Ptx3+/+ and Ptx3–/–
mice at day 0.25, day 1, or day 5 after infection.
Themean value ± SEM is shown. *p% 0.05; ***p%
0.001; two-tailed Mann-Whitney U test.
(D) MPO levels in homogenized Ptx3+/+ and
Ptx3/ bladders and kidneys at day 0.25, day 1,
or day 5 after infection. Results are mean ± SEM.
*p % 0.05; **p % 0.01; ***p % 0.001; two-tailed
Student’s t test.
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In order to address the relevance to man of these findings, we
first assessed the expression of PTX3 in patients suffering from
UTIs. By immunohistochemistry of bladder sections, we
observed a diffuse chronic inflammatory infiltrate associated
with interstitial presence of PTX3 in the subepithelial connective
tissues of patients (Figure 6A, top), whereas PTX3 was not found
or was at very low level in bladder sections of noninfected donors
(Figure 6A, bottom). Serum PTX3 levels were increased in
patients suffering from UTIs compared to healthy donors (Fig-
ure 6B). In particular, APN patients showed the highest levels
(56.06 ± 33.27 ng/ml; mean ± SEM). PTX3 was detected in theImmunity 40, 621–6urine of 20 out of 22 APN patients and in
6 out of 9 cystitis patients, but not in
healthy donors or patients with infections
at distant sites (Erysipelas), who had
serum levels comparable to APN patients
(Figure 6B), suggesting that PTX3 is pro-
duced locally in humans during UTIs. It
should be emphasized that human urine
did not interfere with the ELISA for human
PTX3 (data not shown). Urinary PTX3
levels were higher in patients with APN
(1.33 ± 0.53 ng/ml; mean ± SEM) than in
patients with cystitis (0.24 ± 0.14 ng/ml;
mean ± SEM) or patients carrying
the ABU strain E. coli 83972 (0.11 ±
0.09 ng/ml; mean ± SEM) (Ragnarsdo´ttir
et al., 2010). Moreover, in patients with
APN, PTX3 urinary levels were reduced
during antibiotic treatment from 1.33 ±
0.53 ng/ml to 0.08 ± 0.05 ng/ml (mean ±
SEM) (Figure 6B). In addition, serumPTX3 levels correlated with parameters of disease severity,
such as urea (r = 0.826, p < 0.0001) and creatinine (r = 0.852,
p < 0.0001), but not CRP (r = 0.042, p = 0.87), and urinary
PTX3 levels correlated with hematuria (r = 0.90, p < 0.0001)
(Pearson’s correlation) (Figure S6). Therefore, these results
suggest that local and systemic PTX3 concentration has clinical
relevance to determine the localization of the infection, the
disease severity, and treatment efficacy.
Genetic polymorphisms in the PTX3 locus have been associ-
ated with levels of production and susceptibility to bacterial
infections (Barbati et al., 2012; B. Bottazzi and T. Sprong,
personal communication; Chiarini et al., 2010; May et al., 2010;32, April 17, 2014 ª2014 Elsevier Inc. 627
Figure 6. PTX3 Levels in Human UTIs
(A) Immunostaining analysis for PTX3 in bladder
sections of UTI (top) and healthy (bottom) patients.
Scale bars represent 200 mm.
(B) PTX3 levels in serum and urine of healthy
donors, patients suffering from erysipelas, cystitis,
or pyelonephritis, and patients inoculated with
E. coli 83972 (ABU). Urine of patients with acute
pyelonephritis were collected in Istituto Clinico
Humanitas, Rozzano, Italy (closed circles) or in the
University Hospital for Infectious Diseases,
Zagreb, Croatia (open circles). Results are mean ±
SEM. *p % 0.05; **p % 0.01; ***p % 0.001; two-
tailed Mann-Whitney U test.
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PTX3 in Urinary Tract InfectionOlesen et al., 2007). Similarly, PTX3 polymorphisms were
recently associated with protein levels and susceptibility to
A. fumigatus infection in two cohorts of patients undergoing
bone marrow transplantation (Cunha et al., 2014). Therefore,
we took advantage of well-characterized populations of patients
with ABU, cystitis, or APN and appropriate controls, previously
used for genetic analysis of susceptibility to UTIs (Ragnarsdo´ttir
et al., 2010). We selected a total of 11 SNPs, located in and
around PTX3 from the NCBI SNP database, including those pre-
viously studied (Barbati et al., 2012; Bottazzi et al., 2010; Chiarini
et al., 2010; Cunha et al., 2014; May et al., 2010; Olesen et al.,
2007). Five out of 11 SNPs were polymorphic in our study popu-
lation and reported in Table 1. Interestingly, two intronic SNPs
(rs2305619 and rs1840680) were associated with APN suscepti-
bility and partially with cystitis susceptibility (Tables 1 and S3).
The common homozygote (or ancestral genotype) for these
SNPs (A/A-A/A) occurred in about 30% of controls but was not
present in APN and cystitis patients (Table 1). In contrast, the
heterozygous G/A-G/A and the homozygous G/G-G/G geno-
types were found in significantly increased frequency in the
APN and cystitis patients compared to controls and to primary
ABU patients, who never had symptomatic UTIs (Table 1). The
minor allele frequency for both SNPs was upregulated in APN
(0.65 and 0.70) and cystitis (0.71 and 0.75) patients compared
to control patients (0.45 and 0.49) (Table S3). Haplotype analysis
showed a trend for the A-C-A haplotype (SNPs: rs2305619-
rs3816527-rs184060) to be protective against APN and cystitis
(p = 0.10 and p = 0.05, respectively; Table S4). Thus, our data
show that PTX3 polymorphisms were associated with suscepti-
bility to UTIs.
DISCUSSION
The urinary tract has unique anatomical and functional proper-
ties that call for specialized defense mechanisms and immuno-
regulation (Chan et al., 2013; Dhakal et al., 2008; Ragnarsdo´ttir
et al., 2011). Mechanisms of innate and adaptive resistance
and regulatory circuits in the urinary tract are largely unexplored
and the role, if any, of the humoral arm of innate immunity
(Bottazzi et al., 2010) at this anatomical site remains to be
defined. Here, we report that the humoral pattern recognition
molecule PTX3 is essential for resistance against UTIs. PTX3
had opsonic activity at concentrations observed in tissues during628 Immunity 40, 621–632, April 17, 2014 ª2014 Elsevier Inc.UTIs, accelerating ingestion of bacteria and phagosomematura-
tion in neutrophils. PTX3-deficient neutrophils showed defective
phagocytosis at early time points. The lack of PTX3 resulted in a
long-lasting failure to control infection, its spread, and long-term
consequences (e.g., weight loss). Moreover, PTX3 deficiency
was associated with early and persistent exacerbated inflamma-
tion. Local and rapid expression by epithelial cells, downstream
of the TLR4-MyD88 pathway, supports the presence of PTX3 in
the urinary tract during UTIs to enhance the ingestion of bacteria
by recruited neutrophils. PTX3 was detected in the serum and
urine of patients with UTIs and levels correlated with clinical
parameters of disease severity. Genetic analysis of UTI-prone
patients indicated that PTX3 polymorphisms were associated
with susceptibility to acute pyelonephritis. Thus, PTX3 is
a humoral pattern recognition molecule shown to be involved
in innate immunity against UTIs.
The cellular arm of innate immunity has long been known to
play a key role in resistance against UTIs (Nielubowicz and
Mobley, 2010). Genetic deficiency of TLR4, TLR5, and TLR11,
which act as cellular sensors for microbial moieties and tissue
damage, is associated with increased susceptibility to UTIs
(Andersen-Nissen et al., 2007; Ashkar et al., 2008; Fischer
et al., 2006; Zhang et al., 2004). In the present study we show
that PTX3 is produced by the urothelium during UTIs down-
stream of the protective TLR4-MyD88 pathway. However,
evidence supports that a delicate balance between activation
of protective innate immunity and pathological inflammation is
required for optimal resistance to UTIs (Yadav et al., 2010). For
instance, the TIR-domain containing protein (TcpC) secreted
by UPEC and taken up by host cells inhibits the host immune
response by interfering with TLR signaling and increases the
infection, whereas Myd88/ or Il1b/ infected mice present a
minimal inflammation associated with a lower bacterial load
compared to wild-type animals (Cirl et al., 2008; Yadav et al.,
2010). In addition, IL-10 production in the bladder during UTIs
drives an immunosuppressive response and local tolerance,
which could promote bacterial persistance in the bladder and
facilitate recurrent infections (Chan et al., 2013).
Preclinical and clinical evidence supports that neutrophil
recruitment through the CXCR1/2 axis and neutrophil effector
molecules such as cathelicidin are essential for antimicrobial
resistance at the level of the urinary tract (Chromek et al.,
2006; Frende´us et al., 2000; Kai-Larsen et al., 2010).
Table 1. Genotype Frequency of PTX3 Variants in UTI-Prone Pediatric Patients, Adult Cystitis Patients, and Pediatric Controls
SNP Genotype
Pediatric Primary ABU Pediatric Secondary ABU Pediatric Acute Pyelonephritis Pediatric Controls Adult Cystitis
n (%) n (%) n (%) n (%) n (%)
rs2305619 A/A 6 (46.2) 3 (18.8) 0 (0.0) 12 (30.8) 0 (0.0)
G/A 4 (30.8) 10 (62.5) 14 (70.0) 19 (48.7) 4 (57.0)
G/G 3 (23.1) 3 (18.8) 6 (30.0) 8 (20.5) 3 (43.0)
p value* 0.4948 0.5983 0.0210 - 0.1758
p value** 0.0030 0.1179 - - 0.8246
p value*** - 0.1924 - - 0.0995
rs3816527 C/C 10 (76.9) 11 (68.8) 13 (65.0) 29 (78.4) 3 (34.0)
C/A 1 (7.7) 1 (6.3) 2 (10.0) 1 (2.7) 1 (15.0)
A/A 2 (15.4) 4 (25.0) 5 (25.0) 7 (18.9) 4 (51.0)
p value* 0.7160 0.7016 0.3952 - 0.0619
p value** 0.7595 0.9191 - - 0.3866
p value*** - 0.8153 - - 0.1790
rs1840680 A/A 6 (46.2) 3 (18.8) 0 (0) 11 (28.2) 0 (0.0)
A/G 4 (30.8) 10 (62.5) 12 (60.0) 18 (46.2) 4 (50.0)
G/G 3 (23.1) 3 (18.8) 8 (40.0) 10 (25.6) 4 (50.0)
p value* 0.4649 0.5428 0.0297 - 0.1653
p value** 0.0035 0.0792 - - 0.8899
p value*** - 0.1924 - - 0.0724
rs3845978 C/C 9 (75.0) 16 (100.0) 18 (90.0) 34 (87.2)
C/T 3 (25.0) 0 (0.0) 2 (10.0) 5 (12.8)
T/T 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
p value* 0.5977 0.3236 0.9510 -
p value** 0.5273 0.4287 - -
p value*** - 0.1065 - -
rs2614 C/C 13 (100.0) 16 (100.0) 20 (100.0) 37 (97.4)
C/T 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6)
T/T 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
p value* 0.8399 0.8069 0.7651 -
p value** 1 1 - -
p value*** - 1 - -
Genotype frequencies were compared between patient groups and pediatric controls (*), APN-prone patients (**), and patients with primary ABU (***)
via the contingency chi-square test.
Abbreviation is as follows: ABU, asymptomatic bacteriuria.
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PTX3 in Urinary Tract InfectionOpsonization of pathogens by soluble PRMs may influence
phagocytosis and maturation of the phagosome, two key events
for the elimination of microorganisms (Flannagan et al., 2009; Ip
et al., 2008; Jack et al., 2005). However, the presence and signif-
icance of fluid phase PRMs at the level of the urinary tract has not
been explored. In one study, polymorphisms of MBL2, respon-
sible for low mannose-binding lectin expression levels, were
associated with septic shock after APN, although no differences
were observed between APN patients and healthy controls
(Smithson et al., 2007). Here, we show that PTX3 is a humoral
PRM essential for antimicrobial resistance at the level of the
urinary tract sustaining phagocytic activity and earlier phago-
some maturation.
PTX3 binds outer membrane protein A (OmpA) from
K. pneumoniae, a component of the outer membrane of Entero-
bacteriaceae (Jeannin et al., 2005). OmpA fulfils the classic
criteria for a pathogen-associated molecular pattern, beinghighly conserved among Enterobacteriaceae and essential for
microbial life and pathogenicity. The role of OmpA or other
bacterial surface molecules in interaction of PTX3 with UPEC
remains to be ascertained.
PTX3 was found to be present in mouse and human urine
during UTIs. PTX3 is a 340 kDa octamer and evidence supports
that urinary levels are not a reflection of systemic plasma levels.
Urothelial cells and kidney cells produce PTX3 in response to
inflammatory stimuli (shown here and Nauta et al., 2005). More-
over, neutrophils, which store PTX3 in granules (Jaillon et al.,
2007), are recruited and transmigrate into the urinary tract during
infection. Thus, local production and release of PTX3 by
urothelial cells and leukocytes is the source of this humoral
PRM during UTIs.
In the present study, Ptx3 deficiency was associated with
increased susceptibility to UTIs in terms of infection severity
and pathological inflammation. Indeed, higher levels of bladderImmunity 40, 621–632, April 17, 2014 ª2014 Elsevier Inc. 629
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PTX3 in Urinary Tract Infectionand kidney bacterial burden, neutrophil infiltration, chemokine
levels, and tissue damage were observed in Ptx3/ mice
compared to wild-type mice. Bone marrow chimeras revealed
that both hematopoietic and nonhematopoietic (epithelial)-
derived PTX3 were required for protection against UTIs. These
data are in line with previous studies demonstrating cooperation
between hematopoietic cells and stromal cells for the production
of protective molecules in UTIs (e.g., cathelicidin, CXCR2)
(Chromek et al., 2006; Svensson et al., 2008).
Genetic defects of PRMs have been associated with
increased susceptibility to selected microorganisms (Netea
and van der Meer, 2011). Polymorphisms in the CXCR1, TLR1,
TLR4, TLR5, and IRF3 have been associated with increased
susceptibility to UTIs in humans (Fischer et al., 2010; Hawn
et al., 2009; Lundstedt et al., 2007; Ragnarsdo´ttir et al., 2010,
2011). Here, we report an association between genetic variations
in an essential soluble PRM and APN susceptibility. Two intronic
SNPs (rs2305619 and rs1840680) in PTX3 were associated with
APN susceptibility in terms of frequency and odds ratio. These
two intronic SNPs have previously been associated with
P. aeruginosa colonization in cystic fibrosis patients and
increased risk for pulmonary tuberculosis (Chiarini et al., 2010;
Olesen et al., 2007), suggesting that these SNPs might increase
the risk of bacterial colonization. However, these SNPs increase
the risk for APN and cystitis but not general bacterial colonization
of the bladder because no association of these SNPs, or other
PTX3 SNPs examined here, were observed for the two ABU
groups. Interpretation of haplotype data in relation to previous
studies demonstrating G-A-G as a protective haplotype in other
infections is complicated by the different frequency of PTX3
genetic polymorphisms in the Swedish versus other populations.
In agreement with our data, in a Caucasian population, the A-C-A
haplotype was associated with increased PTX3 plasma levels
and with higher intracellular protein levels in mature neutrophils
(Barbati et al., 2012; Cunha et al., 2014).
The results reported here indicate that PTX3 is a humoral
pattern recognition molecule identified as an essential compo-
nent of resistance against urinary tract infection caused by uro-
pathogenic E. coli, the most prominent cause of urinary tract
infection in humans. Correlative genetic analysis in a previously
characterized, selected human population (Ragnarsdo´ttir et al.,
2010) is consistent with the hypothesis that PTX3 exerts a similar
function in humans. Actually, levels of thismoleculemay serve as
an interesting biomarker of UTIs. Previous studies in preclinical
models similar to that used here and correlative genetic analysis
in the same or similar patient populations have highlighted the
importance of cellular PRMs in resistance against UTIs (Rag-
narsdo´ttir et al., 2011). Thus, the cellular and humoral arms of
innate immunity exert complementary functions in mediating
resistance against UTIs.
EXPERIMENTAL PROCEDURES
Animals
Wild-type C57BL/6J female mice were obtained from Charles River Labora-
tories. Ptx3/ mice were generated as described (Garlanda et al., 2002).
Il1r1/ mice, Myd88/ mice, and Irf3/ mice were kindly provided by J.E.
Sims (Amgen), S. Akira (Osaka University, Osaka, Japan), and K.A. Fitzgerald
(University of Massachusetts Medical School, Worcester, MA), respectively.
Bone marrow transplantation was performed as described in the Supple-630 Immunity 40, 621–632, April 17, 2014 ª2014 Elsevier Inc.mental Experimental Procedures. All mice were used on a C57BL/6J genetic
background. Mice were housed in the SPF animal facility of Istituto Clinico
Humanitas in individually ventilated cages. Procedures involving animals and
their care were conformed with protocols approved by the Istituto Clinico
Humanitas (Rozzano, Milan, Italy) in compliance with national (4D.L. N.116,
G.U., suppl. 40, 18-2-1992) and international (EEC Council Directive 86/609,
OJ L 358,1,12-121987; NIH Guide for the Care and Use of Laboratory Animals,
US National Research Council, 1996) law and policies. All efforts were made to
minimize the number of animals used and their suffering.
Mouse Urinary Tract Infection Model
We used the UPEC strain CFT073 isolated from a patient with acute pyelone-
phritis and the asymptomatic bacteriuria strain E. coli 83972 (Klemm et al.,
2006). Bacteria were cultured 48 hr in Luria-Bertani (LB) medium under static
condition to promote expression of type-1 pili (Hung et al., 2009). The bacteria
were tested for virulence factor expression, including P and Type 1 fimbriae
(Johanson et al., 1993). Bacteria were resuspended in PBS at 1 3 109 CFU/
ml. Mice (8–16 weeks old) were anesthetized with 375 mg/kg Avertin (2,2,2-
Tribromoethanol, 97%, Aldrich) and inoculated with 1 3 108 E. coli in 100 ml
into the bladder by transurethral catheterization with a soft polyethylene
catheter (0.61 mm outer diameter; Clay Adams). Mice were sacrificed on
day 0.25, 1, or 5 after infection. Urine leukocytes collected at day 0.25, 1,
and 5 after infection were counted with a Bu¨rker chamber after staining with
Tu¨rk’s solution and phenotyped by FACS analysis (CD45, clone 30F11;
Ly6G, clone 1A8, both from Becton Dickinson Italia) (Figure S5).
Binding of PTX3 to Bacteria
E. coli CFT073 were cultured 48 hr in Luria-Bertani (LB) medium under static
condition. Bacteria (2 3 108) were washed in PBS and incubated with PTX3
(from 3.2 ng/ml [6.80 3 1011 mol/l] to 50 mg/ml [1.06 3 106 mol/l]) in
PBS2+ or with normal human serum (NHS) (10%). After 30 min at room
temperature, bacteria were extensively washed with PBS2+ and bound pro-
teins were eluted with 4 mM sodium carbonate, 46 mM sodium bicarbonate
(pH 9.2) for 2 hr at 37C. Bacteria were removed by centrifugation (16,000 3
g for 15 min) and the presence of PTX3 in eluted proteins was analyzed by
immunoblotting.
Phagocytosis Assay and Phagosome Maturation
Phagocytosis assay inwhole blood of E. coli strain CFT073 by human andmice
neutrophils was performed as recently described (Moalli et al., 2011). E. coli
strain CFT073 was labeled with CFSE-mixed isomers or Alexa Fluor 647
(Invitrogen) and bacteria, opsonized or not with PTX3, and added to whole
blood as described in Supplemental Experimental Procedures. In contrast to
macrophages, phagosome maturation is not associated to acidification in
neutrophils and a low pH is not required for neutrophil phagosome to be
microbicidal (Jankowski et al., 2002; Nordenfelt and Tapper, 2011). Accord-
ingly, similar results were obtained when bacteria were labeled with CFSE or
with a pH-insensitive dye Alexa Fluor 647 (data not shown). The phagosome
maturation protocol is described in Supplemental Experimental Procedures.
Urothelial Cell Stimulation
The human nonmalignant urothelial cell line HCV29was stimulatedwith TNF-a,
IL-1b (R&D Systems), or E. coli strain CFT073 at the indicated concentra-
tions or multiplicity of infection (MOI), respectively. Additional information is
available in Supplemental Experimental Procedures.
Quantitative PCR
PTX3mRNA expression in urothelial cells was determined by quantitative PCR
as described in the Supplemental Experimental Procedures.
Analysis of PTX3 Expression by Immunoblotting
Presence of PTX3 in urine and in proteins eluted from bacteria was analyzed by
immunoblotting with affinity-purified rabbit IgG against PTX3. Additional
information is available in Supplemental Experimental Procedures.
Patients
A cohort consisting of UTI-prone children (n = 49) from Southern Sweden, as
well as age-matched children controls (n = 39) and adult cystitis patients
Immunity
PTX3 in Urinary Tract Infection(n = 9) from the same geographic area, was examined for PTX3 SNP variability.
Patient characteristics are described in Supplemental Experimental Proce-
dures. Written consent was obtained from all participants or their parents/
guardians. This study was approved by the ethics committees of the medical
faculty, Lund University, Sweden (LU106-02, LU236-99), of the Istituto Clinico
Humanitas, Rozzano, Italy (ICH-99/09), and of the University Hospital for Infec-
tious Diseases, Zagreb, Croatia (17.02.2006 and 15.12.2011).
Genomic DNA Sampling and Pyrosequencing
Genomic DNA was extracted from heparinized peripheral blood via QIAamp
DNA Blood Midi kit (QIAGEN). PTX3 SNPs from patients prone to UTIs or
healthy controls were genotyped with Pyrosequencer PSQ 96 (QIAGEN) after
PCR amplification of chromosomal DNA and a second biotinylated PCR for
each SNP. More detailed descriptions of inclusion criteria and diagnosis are
provided in previous studies (Lundstedt et al., 2007; Ragnarsdo´ttir et al.,
2010). Primers were designed according to the published sequence for the
PTX3 gene (Tables S5 and S6).
Additional methods, including histological and immunohistochemistry
analysis; tissue homogenization; PTX2, myeloperoxidase (MPO), and cytokine
analysis; and statistical analysis can be found in the Supplemental Experi-
mental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, six tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2014.02.015.
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